Michael Barbella, Managing Editor01.13.24
Old favorites took center stage in the second week of this new year.
Personnel, product innovation, and a lone purchase drove the bulk of ODT website traffic over the last seven days. Top 10 Company alumnists Stryker Corp. and Smith+Nephew enticed cybervisitors with their respective product announcements while Orthofix and Zimmer Biomet attracted digital guests with new recruits.
Stryker led the charge by completing the first shoulder replacement surgeries using its Blueprint mixed reality (MR) guidance which combines the company’s software with the Microsoft HoloLens 2 headseat, allowing surgeons to track their instrumentation’s position and orientation in the physical environment. Surgeons and their instruments are guided by 3D images and guidance widgets displayed on the patient and in the line of sight.
Smith+Nephew gained favor with ODT loyalists by releasing promising results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online last month in Arthroscopy, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care.
Orthofix Medical Inc., meanwhile, made cyberwaves earlier this week as Massimo Calafiore assumed the helm and Julie Andrews joined the firm as chief financial officer (CFO). Andrews previously served as CFO for Smart Wires Technology, where she led all finance, tax, treasury, accounting, information technology, and investor relations functions. Zimmer Biomet Holdings Inc. followed suit via the appointment of former Hospital for Special Surgery President/CEO Louis A. Shapiro to its board, effective immediately.
Finally, OrthoPediatrics amassed pageviews by purchasing Boston Orthotics & Prosthetics, a company that has focused on pediatric orthotic management for more than 50 years. The company also revealed closing of debt financing with MidCap Financial, providing up to $80 million of capital through a term loan and revolving loan.
Personnel, product innovation, and a lone purchase drove the bulk of ODT website traffic over the last seven days. Top 10 Company alumnists Stryker Corp. and Smith+Nephew enticed cybervisitors with their respective product announcements while Orthofix and Zimmer Biomet attracted digital guests with new recruits.
Stryker led the charge by completing the first shoulder replacement surgeries using its Blueprint mixed reality (MR) guidance which combines the company’s software with the Microsoft HoloLens 2 headseat, allowing surgeons to track their instrumentation’s position and orientation in the physical environment. Surgeons and their instruments are guided by 3D images and guidance widgets displayed on the patient and in the line of sight.
Smith+Nephew gained favor with ODT loyalists by releasing promising results for its REGENETEN Bioinductive Implant from a recently completed randomized controlled trial (RCT). Published online last month in Arthroscopy, the report concluded that at one-year, medium and large full-thickness rotator cuff tears repaired and augmented with the REGENETEN Bioinductive Implant had better tendon healing compared to the standard of care.
Orthofix Medical Inc., meanwhile, made cyberwaves earlier this week as Massimo Calafiore assumed the helm and Julie Andrews joined the firm as chief financial officer (CFO). Andrews previously served as CFO for Smart Wires Technology, where she led all finance, tax, treasury, accounting, information technology, and investor relations functions. Zimmer Biomet Holdings Inc. followed suit via the appointment of former Hospital for Special Surgery President/CEO Louis A. Shapiro to its board, effective immediately.
Finally, OrthoPediatrics amassed pageviews by purchasing Boston Orthotics & Prosthetics, a company that has focused on pediatric orthotic management for more than 50 years. The company also revealed closing of debt financing with MidCap Financial, providing up to $80 million of capital through a term loan and revolving loan.